Analysis of Multimerin 1 (MMRN1) expression in ovarian cancer
- PDF / 1,055,906 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 67 Downloads / 187 Views
ORIGINAL ARTICLE
Analysis of Multimerin 1 (MMRN1) expression in ovarian cancer Abhinav Saini1 · Kumari Binita Chandra1 · Vikrant Kumar1 · Sandeep R Mathur2 · J B Sharma3 · Sunesh Kumar3 · Savita Yadav1 Received: 15 May 2020 / Accepted: 20 November 2020 © Springer Nature B.V. 2020
Abstract Ovarian cancer, the most lethal gynecological cancer, is the fifth most common cause of cancer-related deaths in women. A cost-effective and non-invasive early screening method for ovarian cancer is required to reduce the high mortality rate. Saliva is a clinically informative unique fluid, which is useful for novel approaches to prognosis, clinical diagnosis, and monitoring for non-invasive detection of disease. Multimerin1 (MMRN1) is a di-sulfide linked homo-polymeric glycoprotein from EMILIN family. Altered expression of MMRN1 has been reported in hepatocellular carcinoma, cervical cancer, and ovarian cancer. But, its role in epithelial ovarian cancer (EOC) is not clear and well documented. In this study, expression of Multimerin 1 was validated in saliva and tissues of EOC patients and age-matched controls by western blotting, ELISA, RT-PCR, and immunohistochemistry. Significant over expression of MMRN1 was observed by western blot and ELISA in saliva samples of EOC patients. The average concentration of MMRN1 in the saliva of healthy controls was 28.7 pg/ml (SE ± 1.76), 42.53 pg/ml (SE ± 4.06) in low grade and 52.91 pg/ml (SE ± 4.24) with p
Data Loading...
